PARP Inhibitors

PARP inhibitors are used to treat advanced prostate cancer that has spread to other parts of the body and has stopped responding to hormone treatments that lower testosterone.

What are PARP inhibitors?

PARP inhibitors are a type of targeted treatment used to treat prostate cancer that has: 

  • spread to other parts of the body and
  • stopped responding to treatment that lowers testosterone. 

This is called metastatic castrate resistant prostate cancer (mCRCP) 

Image
olaparib

How do PARP inhibitors work?

  • DNA is found in every cell. It carries the instructions that help cells grow and survive. 

  • Cancer cells often have damaged DNA and problems repairing it properly. 

  • PARP is a protein found in cells that helps repair damaged DNA. 

  • PARP inhibitors block the PARP protein. 

  • When this happens, cancer cells can no longer repair their damaged DNA. 

  • Over time, the damage builds up and the cancer cells can no longer survive. 

  • Normal cells are usually better at repairing DNA, so they are less affected.

Image
Illustration showing a cell, chromosome, gene and DNA

Important things to know

 

What are the benefits of PARP inhibitors? 

If you take a PARP inhibitor, your prostate cancer may take longer to get worse (progress).

When are PARP inhibitors used?

PARP inhibitors may be used to treat metastatic castrate-resistant prostate cancer (mCRPC).  

There are two types of PARP inhibitors used to treat metastatic castrate resistant prostate cancer. 

  • Olaparib 
  • Talazoparib 

 Olaparib on its own 

You may have olaparib on its own if you: 

  • Have metastatic castrate-resistant prostate cancer and
  • Are having hormone injections or taking relugolix tablets, and
  • Have already had hormone tablets, such as abiraterone or enzalutamide, and your prostate cancer has started to grow again
  • Have a faulty BRCA gene shown on prostate biopsy testing. This can be found by testing samples from your prostate biopsy

 Olaparib with abiraterone 

You may have olaparib together with: 

  • Abiraterone (a hormone tablet), and
  • A steroid tablet (prednisone or prednisolone) 

If you: 

  • Have metastatic castrate-resistant prostate cancer, and
  • Have not been treated before with hormone tablets such as abiraterone, apalutamide, enzalutamide, or darolutamide, and
  • Cannot have, or do not want to have, chemotherapy, and
  • Live in England, Scotland, or Wales 

This treatment is not currently available in Northern Ireland. 

 Talazoparib 

You may have talazoparib if you: 

  • Have metastatic castration-resistant prostate cancer and 
  • Talazoparib would be your first treatment for metastatic castration-resistant prostate cancer and

  • You are having hormone injections or relugolix tablets, and  

  • You are taking enzalutamide tablets, and
  • You cannot have chemotherapy and 
  • You are unable to take abiraterone plus prednisolone 

  • You live in England, Scotland or Wales. It is not currently available in Northern Ireland.

You do not need to have a BRCA gene fault to receive Talazoparib

Frequently asked questions about PARP inhibitors

About this information

  • This information was updated in February 2026. Date of next review: February 2028.
  • References and bibliography available on request.
  • If you want to reproduce this content, please see our Reproducing Our Content page.

What is risk?

  • Risk is the chance something bad could happen when we do something. Even simple things such as walking down the stairs can have risks. But we take risks because we think it will be worth it. We need to think about both the benefits and risks of what might happen when we do something.
  • You should always ask your healthcare team about both the benefits and risks of any treatment.
  • Remember if they tell you about a risk, it doesn‘t mean it will happen to you. They may say one man in ten who has this treatment will have a side effect. But they can‘t tell you if you will be the ‘one’ man who gets this side effect.
Image
Risk vs Benefit
What are the side effects of PARP inhibitors?

About this information

  • This information was published in April 2024. Date of next review: February 2028.
  • References and bibliography available on request.
  • If you want to reproduce this content, please see our Reproducing Our Content page.

What is the impact?

  • We asked real visitors to the infopool to share their experience of this treatment. They told us how this treatment had impacted their everyday lives in a number of different areas.
  • The numbers and images below represent how many people said this treatment had impacted them ‘a lot’ in each of the different areas.
  • For example, imagine it says ‘25 in 100’ underneath ‘physical and social wellbeing’. This means that 25 out of 100 people who shared their experience of this treatment told us it impacted their ‘physical and social wellbeing’ a lot. However it would also mean that 75 out of 100 people said it had not impacted them a lot.

Please note: Olaparib is still a fairly new treatment. This means that we do not as yet have enough stories to feed into the images. The images will update as more people share their stories about being treated with Olaparib. 

Physical and social wellbeing

Enjoying activities such as walking or going out to the pub

100 out of 100

Effect on relationships

Ability to make good connections with others

100 out of 100

Sexual activity

Ability to reach sexual arousal, either physically or emotionally

100 out of 100

Sense of self

Knowing who you are and what motivates you

100 out of 100

Wellbeing and quality of life

Feeling good and functioning well in your personal and professional life

100 out of 100

Mental and emotional health

Ability to think clearly, make good decisions, and cope with your emotions

100 out of 100

Fatigue

Feeling of constant physical and/or mental tiredness or weakness

100 out of 100

1
Showing 1 patient stories containing PARP Inhibitors
Video

Share your story with others

By sharing your experience of prostate cancer on the infopool you can help others. Your experience is valuable as they go through their own journey. Help make the prostate cancer community stronger.

Share story